Have a personal or library account? Click to login
Development of a HPLC-UV method for determination of meloxicam in human plasma and pharmaceutical dosage forms Cover

Development of a HPLC-UV method for determination of meloxicam in human plasma and pharmaceutical dosage forms

Open Access
|Nov 2014

References

  1. 1. Shaji J, Varkey D. Development and validation of a reverse phase-hplc method for determination of meloxicam in pharmaceutical dosage forms and human plasma. Int J Pharm Sci Rev Res. 2012;12:152-160.
  2. 2. Kimble B, Li KM, Govendir M. Quantitation of meloxicam in the plasma of koalas (Phascolarctos cinereus) by improved high performance liquid chromatography. J Vet Sci. 2013;14:7-14.10.4142/jvs.2013.14.1.7
  3. 3. Bandarkar FS, Vavia PR. A Stability Indicating HPLC Method for the Determination of Meloxicam in Bulk and Commercial Formulations. Tropical Journal of Pharmaceutical Research. 2009;8:257-264.
  4. 4. Reddy MN, Murthy TK, Rajita K, Shankar DG. New Spectrophotometric Methods For The Determination Of Meloxicam. Indian J Pharm Sci. 2001;63:245-247.
  5. 5. Zawilla NH, Abdul-Azim Mohammad M, El Kousy NM, El-Moghazy Aly SM. Determination of meloxicam in bulk and pharmaceutical formulations. J Pharm Biomed Anal. 2003;32:1135-1144.10.1016/S0731-7085(03)00232-2
  6. 6. Murarasu AE, Mandrescu M, Spac AF, Dorneanu V. A method for the turbidity assay of meloxicam using molybdophosphoric acid. Farmacia. 2010;58:315-321.
  7. 7. Altinoz S, Nemutlu E, Kir S. Polarographic behaviour of meloxicam and its determination in tablet preparations and spiked plasma. Farmaco. 2002;57:463-468.10.1016/S0014-827X(02)01239-9
  8. 8. Nemutlu E, Kir S. Method development and validation for the analysis of meloxicam in tablets by CZE. J Pharm Biomed Anal. 2003;31:393-396.10.1016/S0731-7085(02)00641-6
  9. 9. Zhang H, Choi H. Analysis of meloxicam by high-performance liquid chromatography with cloud-point extraction. Anal Bioanal Chem. 2008;392:947-953.10.1007/s00216-008-2333-0
  10. 10. Rao RN, Meena S, Rao AR. An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. J Pharm Biomed Anal. 2005;39:349-363.10.1016/j.jpba.2005.03.040
  11. 11. Vignaduzzo SE, Castellano PM, Kaufman TS. Method development and validation for the simultaneous determination of meloxicam and pridinol mesylate using RP-HPLC and its application in drug formulations. J Pharm Biomed Anal. 2008;46:219-225.10.1016/j.jpba.2007.09.011
  12. 12. Velpandian T, Jaiswal J, Bhardwaj RK, Gupta SK. Development and validation of a new high-performance liquid chromatographic estimation method of meloxicam in biological samples. J Chromatogr B Biomed Sci Appl. 2000;738:431-436.10.1016/S0378-4347(99)00537-X
  13. 13. Dasandi B, Shivaprakash, Saroj H, Bhat KM. LC determination and pharmacokinetics of meloxicam. J Pharm Biomed Anal. 2002;28:999-1004.10.1016/S0731-7085(02)00064-X
  14. 14. Rigato HM, Mendes GD, Borges NC, Moreno RA. Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. Int J Clin Pharmacol Ther. 2006;44:489-498.10.5414/CPP4448917063980
  15. 15. Sinha PK, Jeswani RM, Topagi KS, Damle MC. A validated RP-HPLC method for determination of Meloxicam in the Presence of its Impurities. International Journal of PharmTech Research. 2009;1:1051-1060.
DOI: https://doi.org/10.2478/amma-2014-0031 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 142 - 145
Submitted on: Apr 11, 2014
Accepted on: Aug 19, 2014
Published on: Nov 25, 2014
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2014 Csifo Enikő, Croitoru M. D., Fülöp Ibolya, Muntean Daniela-Lucia, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.